Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry
Mucopolysaccharidoses (MPS) are a group of inborn errors of metabolism that are progressive and usually result in irreversible skeletal, visceral, and/or brain damage, highlighting a need for early diagnosis.
This pilot study analyzed 2862 dried blood spots (DBS) from newborns and 14 DBS from newborn patients with MPS (MPS I, n = 7; MPS II, n = 2; MPS III, n = 5). Disaccharides were produced from polymer GAGs by digestion with chondroitinase B, heparitinase, and keratanase II. Heparan sulfate (0S, NS), dermatan sulfate (DS) and mono- and di-sulfated KS were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS). Median absolute deviation (MAD) was used to determine cutoffs to distinguish patients from controls. Cutoffs were defined as median + 7× MAD from general newborns.
The cutoffs were as follows: HS-0S > 90 ng/mL; HS-NS > 23 ng/mL, DS > 88 ng/mL; mono-sulfated KS > 445 ng/mL; di-sulfated KS > 89 ng/mL and ratio di-KS in total KS > 32 %. All MPS I and II samples were above the cutoffs for HS-0S, HS-NS, and DS, and all MPS III samples were above cutoffs for HS-0S and HS-NS. The rate of false positives for MPS I and II was 0.03 % based on a combination of HS-0S, HS-NS, and DS, and for MPS III was 0.9 % based upon a combination of HS-0S and HS-NS.
Combination of levels of two or more different GAGs improves separation of MPS patients from unaffected controls, indicating that GAG measurements are potentially valuable biomarkers for newborn screening for MPS.
KeywordsNewborn Screening Dermatan Sulfate Keratan Sulfate Median Absolute Deviation Newborn Screen
This work was supported by grants from Japanese MPS Society, the Austrian MPS Society, The Bennett Foundation, and International Morquio Organization (Carol Ann Foundation). R.W.M. and S.T. were supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of NIH under grant numbers P20GM103464 and P30GM114736. S.T. and A.M were supported by National Institutes of Health grant 1R01HD065767. F.K. was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico, from Brazil (CNPq). The content of the article has not been influenced by the sponsors. We also appreciate individual patients with MPS, who participated in projects of “Newborn screening and biomarkers for Mucopolysaccharidoses.”
Compliance with ethics guidelines
Conflict of interest
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). The study was approved by Nemours IRB (protocol 281495). Informed consent was obtained from all patients for being included in the study.
- Lin SP, Lin HY, Wang TJ et al (2013) A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis 22:1–8Google Scholar
- Neufeld E, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452Google Scholar
- Oguma T, Tomatsu S, Montaño AM et al (2007) Analytical method for determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem 368:79–86CrossRefPubMedGoogle Scholar
- R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. (http://www.R-project.org/)
- Ruijter GJ, Goudriaan DA, Boer AM et al (2014) Newborn screening for hunter disease: a small-scale feasibility study. J Inherit Metab Dis Rep 14:23–27Google Scholar
- Shimada T, Tomatsu S, Yasuda E et al (2014b) Chondroitin 6-sulfate as a novel biomarker for mucopolysaccharidosis type I, IIIA, IVA and VII. J Inherit Metab Dis Rep 16:15–24Google Scholar
- Shimada T, Tomatsu S, Mason RW et al (2015) Di-sulfated KS as a novel biomarker for mucopolysaccharidosis II, IVA, and IVB. J Inherit Metab Dis Rep 21:1–13Google Scholar
- U.S. Department of Health and Human Services (2001) Guidance for Industry. Bioanalytical method validation. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). Available at: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070107.pdf